vs
Side-by-side financial comparison of Expensify, Inc. (EXFY) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $35.2M, roughly 1.6× Expensify, Inc.). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -4.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 2.4%).
Expensify, Inc. is a software company that develops an expense management system for personal and business use. Expensify also offers a business credit card called the Expensify Card.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
EXFY vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $57.3M |
| Net Profit | — | $-47.5M |
| Gross Margin | 49.2% | 91.6% |
| Operating Margin | -11.2% | -82.2% |
| Net Margin | — | -83.0% |
| Revenue YoY | -4.9% | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | $-0.07 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | $57.3M | ||
| Q3 25 | $35.1M | $51.3M | ||
| Q2 25 | $35.8M | $48.5M | ||
| Q1 25 | $36.1M | $32.7M | ||
| Q4 24 | $37.0M | $41.8M | ||
| Q3 24 | $35.4M | $33.3M | ||
| Q2 24 | $33.3M | $29.1M | ||
| Q1 24 | $33.5M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-2.3M | $-52.9M | ||
| Q2 25 | $-8.8M | $-46.6M | ||
| Q1 25 | $-3.2M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $-2.2M | $-43.6M | ||
| Q2 24 | $-2.8M | $-32.3M | ||
| Q1 24 | $-3.8M | $-141.4M |
| Q4 25 | 49.2% | 91.6% | ||
| Q3 25 | 49.6% | 89.3% | ||
| Q2 25 | 51.9% | 88.6% | ||
| Q1 25 | 50.6% | 88.8% | ||
| Q4 24 | 51.0% | 90.9% | ||
| Q3 24 | 51.6% | 88.5% | ||
| Q2 24 | 56.9% | 89.9% | ||
| Q1 24 | 56.5% | 89.2% |
| Q4 25 | -11.2% | -82.2% | ||
| Q3 25 | -6.4% | -102.6% | ||
| Q2 25 | -28.9% | -93.4% | ||
| Q1 25 | -4.1% | -143.7% | ||
| Q4 24 | 1.3% | -98.6% | ||
| Q3 24 | 0.8% | -132.0% | ||
| Q2 24 | 0.7% | -139.2% | ||
| Q1 24 | -5.3% | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | -6.6% | -103.1% | ||
| Q2 25 | -24.6% | -96.1% | ||
| Q1 25 | -8.8% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | -6.2% | -131.2% | ||
| Q2 24 | -8.3% | -110.9% | ||
| Q1 24 | -11.3% | -544.4% |
| Q4 25 | $-0.07 | $-0.73 | ||
| Q3 25 | $-0.03 | $-0.82 | ||
| Q2 25 | $-0.10 | $-0.75 | ||
| Q1 25 | $-0.03 | $-0.81 | ||
| Q4 24 | $-0.03 | $-0.71 | ||
| Q3 24 | $-0.02 | $-0.73 | ||
| Q2 24 | $-0.03 | $-0.55 | ||
| Q1 24 | $-0.04 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.1M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $132.7M | $139.1M |
| Total Assets | $186.0M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.1M | $388.9M | ||
| Q3 25 | $61.5M | $416.1M | ||
| Q2 25 | $60.5M | $291.0M | ||
| Q1 25 | $59.6M | $314.5M | ||
| Q4 24 | $48.8M | $320.6M | ||
| Q3 24 | $39.2M | $298.4M | ||
| Q2 24 | $53.2M | $319.1M | ||
| Q1 24 | $49.3M | $201.2M |
| Q4 25 | $132.7M | $139.1M | ||
| Q3 25 | $135.7M | $148.8M | ||
| Q2 25 | $131.8M | $-11.9M | ||
| Q1 25 | $134.7M | $18.9M | ||
| Q4 24 | $128.2M | $21.7M | ||
| Q3 24 | $119.9M | $11.2M | ||
| Q2 24 | $114.0M | $39.3M | ||
| Q1 24 | $106.5M | $61.6M |
| Q4 25 | $186.0M | $480.2M | ||
| Q3 25 | $186.8M | $506.9M | ||
| Q2 25 | $187.1M | $372.7M | ||
| Q1 25 | $189.2M | $386.7M | ||
| Q4 24 | $173.7M | $392.3M | ||
| Q3 24 | $176.2M | $363.6M | ||
| Q2 24 | $192.9M | $381.8M | ||
| Q1 24 | $184.8M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.2M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.2M | $-25.4M | ||
| Q3 25 | $4.2M | $-26.6M | ||
| Q2 25 | $8.9M | $-23.3M | ||
| Q1 25 | $4.8M | $-40.4M | ||
| Q4 24 | $7.4M | $-18.8M | ||
| Q3 24 | $3.7M | $-25.2M | ||
| Q2 24 | $9.3M | $-29.1M | ||
| Q1 24 | $3.5M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
